亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        聲稱可延緩阿爾茨海默病進程的藥物獲FDA批準

        2023-10-02 23:26:55胡靜
        求學·理科版 2023年18期
        關鍵詞:胡靜肌萎縮阿爾茨海默

        胡靜

        In early July, FDA granted traditional full approval of Leqembi for the treatment of Alzheimers disease (AD). This is the first approved medication proven to slow the progression of ADs clinical symptoms. A phase three trial among 50- to 90-year-old patients with early AD showed that it can do so by about 27% over an 18-month period. While we cannot extrapolate(推斷) beyond 18 months, this represents about a six-month delay in progression of AD symptoms.

        A second disease-slowing drug, donanemab, has recently shown similar effects and may get FDA approval by the end of the year. The development of Leqembi is a notable success for medical science in that a disease previously impervious to any disease-modifying medical intervention now has an available, effective treatment. However, paraphrasing Winston Churchill, this is not the beginning of the end but the end of the beginning. The drug does not reverse disease symptoms or prevent progression, it slows progression. And there are considerations that make it inappropriate for many patients with AD. It does, however, lay the groundwork for future AD medications that could alleviate(減輕) suffering from this devastating disease for generations to come.

        An important factor for new drugs is their cost. Leqembis price tag is $26,500 per year—much more than the current symptomatic medications for AD but comparable or less expensive than new medications for other conditions, for example multiple sclerosis or ALS.

        Medicare has announced that it will provide coverage for this medication, although it is requiring that physicians perform certain clinical measures and enter the patients data in a registry in order for the drug to be covered, which will increase physician and patient burdens. Whats more, traditional Medicare only covers 80% of outpatient costs, so for those patients without supplemental insurance, a 20% copay for the drug and required MRI scans(核磁共振掃描) might amount to up to $10,000 or more per year out of pocket, but still only a fraction of the cost of a year of in a nursing home.

        (材料來自CNN網站,有刪改)

        1. What can we learn from the first two paragraphs?

        A. Leqembi can make a six-month delay of ADs symptoms over a two-year period.

        B. To some degree, Leqembi is effective to slow the progression of AD symptoms.

        C. Both donanemab and Leqembi have got FDA approval.

        D. The drug is appropriate for any patient with AD.

        2. The underlined sentence in Paragraph 2 means _____ in the passage.

        A. although the new drug has undergone trials, it is still not effective enough

        B. though Leqembi is proven to slow the progression of ADs symptoms, we still have a long way to go

        C. the research of the Leqembi will come to an end

        D. some others problems related to the the medicine have been caused

        3. Leqembis price is _____ according to the passage.

        A. much cheaper than other medications for AD

        B. much more than current medications for other conditions

        C. affordable to almost every patient

        D. cheaper than new medications for ALS

        4. Medicare will provide coverage for this medication on condition that _____.

        A. physician and patient burdens are increased

        B. patients do not have supplemental insurance

        C. patients data is registered and clinical measures are carried out by doctors

        D. patients pay the cost of a year of in a nursing home

        1. B。解析:細節(jié)理解題。根據(jù)材料第一段中的實驗結果和第二段中的“The drug does not reverse disease symptoms or prevent progression, it slows progression.”,我們可知這種藥物不能逆轉疾病癥狀或阻止病情發(fā)展,但它可以減緩病情進展。故選B。

        2. B。解析:句意猜測題。根據(jù)材料第二段中的“And there are considerations that make it inappropriate for many patients with AD. It does, however, lay the groundwork for future AD medications that could alleviate suffering from this devastating disease for generations to come.”,我們可知雖然Leqembi這一藥物能起到延緩病情的效果,但是目前其仍舊存在局限性。故選B。

        3. D。解析:細節(jié)理解題。材料第三段提到:使用Leqembi的話,每年需花費26500美元,費用遠遠超過目前的對癥藥物,但這一費用與治療其他疾病(如多發(fā)性硬化或肌萎縮側索硬化)的新藥物價格相當或是比它們更便宜。故選D。

        4. C。解析:細節(jié)理解題。根據(jù)材料最后一段中的“Medicare has announced that it will provide coverage for this medication, although it is requiring that physicians perform certain clinical measures and enter the patients data in a registry in order for the drug to be covered.”,我們可知承保條件是醫(yī)生執(zhí)行某些臨床措施并錄入患者的數(shù)據(jù)。故選C。

        猜你喜歡
        胡靜肌萎縮阿爾茨海默
        2023年春節(jié),旅游業(yè)強勁復蘇
        阿爾茨海默病的預防(下)
        中老年保健(2022年2期)2022-08-24 03:21:24
        阿爾茨海默病的預防(上)
        中老年保健(2022年1期)2022-08-17 06:14:36
        Nonlinear oscillation characteristics of magnetic microbubbles under acoustic and magnetic fields
        Theoretical model and experimental investigation optically triggered hollowcathode discharge formation
        睡眠不當會增加阿爾茨海默風險
        奧秘(2018年9期)2018-09-25 03:49:56
        額顳葉癡呆伴肌萎縮側索硬化1例
        CH25H與阿爾茨海默病
        肌萎縮側索硬化癥的重復電刺激研究
        腓骨肌萎縮癥SIMPLE基因突變分析
        国产成人国产在线观看入口| 国产一区二区三区小说| 国产人与zoxxxx另类| 99久久精品免费看国产情侣| 麻豆av一区二区天堂| 高潮内射主播自拍一区| 色综合久久精品亚洲国产| 自拍偷自拍亚洲精品播放| 国产毛片三区二区一区| 亚洲av无一区二区三区久久蜜桃 | 亚洲国产精品一区二区www| 精品高潮呻吟99av无码视频| 久久精品日本美女视频| 中文字幕中文字幕在线中二区| 青春草在线视频免费观看| 欧美日韩精品乱国产538| 永久免费中文字幕av| 精品日韩一级免费视频| 亚洲国产精品va在线播放| 久久av高潮av喷水av无码| 亚洲高清激情一区二区三区| 亚洲av色欲色欲www| 国产精品卡一卡二卡三| 日韩免费无码一区二区三区| 午夜短无码| 国产一区二区亚洲一区| 国产美女爽到喷出水来视频| 国产亚洲美女精品久久久| 国产亚洲av人片在线播放| 亚洲国产中文字幕一区| 性色av无码中文av有码vr| 久久久99精品成人片中文字幕 | 欧美乱人伦中文字幕在线不卡| 宅男天堂亚洲一区二区三区| 国语自产偷拍在线观看| 少妇的丰满3中文字幕| 国产av一区二区三区在线| 亚洲最大成人网站| 成人h动漫精品一区二区| 国产日产久久福利精品一区| 亚洲悠悠色综合中文字幕|